European Association of Urology Congress | Conference

Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate Cancer

July 12th 2021

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 12th 2021

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Darolutamide Demonstrates Favorable Tolerability in Nonmetastatic CRPC

July 12th 2021

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Abiraterone/Prednisone Combo Linked With Improvements in Fatigue and QoL, But Worsening Metabolic Changes in mCRPC

July 12th 2021

Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.

Darolutamide Crossover Leads to High PSA Response in Nonmetastatic CRPC

July 12th 2021

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.

Apalutamide Plus ADT Improves Survival Regardless of Disease Volume in mCSPC

July 12th 2021

Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Sequential Mitomycin/BCG Combo Shows Preliminary Safety in High-Risk NMIBC

July 10th 2021

Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 10th 2021

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

July 10th 2021

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Urologic Care Rates Decline Across US Demographics During Height of COVID-19 Pandemic

July 9th 2021

The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.